Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 14/20 | 0.51 |
| ▸ | FAP | Q12884 | 5/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.48 |
| ▸ | MAOB | P27338 | 1/20 | 0.48 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.48 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 3/20 | 0.46 |
| ▸ | HTR2A | P28223 | 3/20 | 0.46 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5718843 | 0.93 | DPP4 (0.47) | DPP4FAPADORA3MAOBADORA2A | |
| SCHEMBL5789590 | 0.86 | DPP4 (0.59) | DPP4MAOBADORA2AHTR1AHTR2A | |
| SCHEMBL5788088 | 0.86 | ALDH1A1 (0.57) | DPP4FAPALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5719382 | 0.85 | ADORA1 (0.50) | DPP4FAPADORA3MAOBADORA2A | |
| SCHEMBL5789175 | 0.84 | ALDH1A1 (0.53) | DPP4FAPL3MBTL1ALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL5718991 | 0.82 | DPP4 (0.47) | DPP4FAPHTR1AHTR2AL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL5719143 | 0.81 | DPP4 (0.53) | DPP4FAPL3MBTL1ALDH1A1 | |
| SCHEMBL5718995 | 0.81 | DPP4 (0.44) | DPP4FAPHTR1AHTR2AL3MBTL1 | |
| Trifluoroacetic Acid SCHEMBL5719425 | 0.81 | DPP4 (0.51) | DPP4FAPMAOBADORA2AADORA1 | |
| Trifluoroacetic Acid SCHEMBL5719128 | 0.81 | LMNA (0.47) | DPP4FAPHTR1AHTR2AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | US | claimed |
| EP-1338595-A2 | Xanthine derivatives as DPP-IV inhibitors | Eisai Co., Ltd. (JP) | 2003-08-27 | — | — | EP | claimed |
| US-7074798-B2 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD (JP) | 2006-07-11 | — | — | US | disclosed |
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | EISAI CO., LTD. (JP) | 2004-04-29 | — | — | US | disclosed |
| EP-1338595-A2 | Xanthine derivatives as DPP-IV inhibitors | Eisai Co., Ltd. (JP) | 2003-08-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040082570-A1 | Xanthine derivative and DPPIV inhibitor | DPP4, DPP9, DPP7 | DPP4 1/4885FAP 402/4885ADORA3 70/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.